| A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (NCT05212922) | Eucure (Beijing) Biopharma Co., Ltd | 2023-06-01 |
| Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma (NCT05564806) | Eucure (Beijing) Biopharma Co., Ltd | 2023-01-31 |
| A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma (NCT05420324) | Eucure (Beijing) Biopharma Co., Ltd | 2022-06-13 |
| A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects with Advanced Solid Tumors (NCT05176509) | Eucure (Beijing) Biopharma Co., Ltd | 2022-04-05 |
| A Study to Assess YH002 in Combination with YH001 in Subjects with Advanced Solid Tumors (NCT05169697) | Eucure (Beijing) Biopharma Co., Ltd | 2022-02-21 |
| Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy (NCT05040932) | Eucure (Beijing) Biopharma Co., Ltd | 2021-12-07 |
| A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors (NCT05017623) | Eucure (Beijing) Biopharma Co., Ltd | 2021-08-26 |
| A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors (NCT04699929) | Eucure (Beijing) Biopharma Co., Ltd | 2021-01-26 |
| A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors (NCT04481009) | Eucure (Beijing) Biopharma Co., Ltd | 2020-08-04 |
| A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies (NCT04353102) | Eucure (Beijing) Biopharma Co., Ltd | 2020-04-22 |
| A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors (NCT04357756) | Eucure (Beijing) Biopharma Co., Ltd | 2020-04-21 |